Key facts
- It has raised $2.6M across 1 recorded rounds; the latest was Seed Round in Mar 2025.
- Notable investors include TEDCO, Abell Foundation, University of Maryland, Baltimore, The University System of Maryland Momentum Fund — 6 tracked in total.
- Irazu Oncology has filed 1 Form D with the SEC, most recently Dec 2023 ($2.6M sold to 6 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Irazu Oncology
Funding rounds
1 roundsAbout Irazu Oncology
Developer of a vaccine platform designed to improve clinical outcomes for cancer patients. The company develops novel, effective, and cost-effective cancer vaccines that initially target colorectal cancer in patients, enabling medical researchers to easily target multiple malignancies and stimulate the body's immune system to attack and destroy tumor cells.
- Sector
- Healthcare
- HQ
- Baltimore, MD, United States
- Founded
- 2022
- Employees
- 9
- Website
- irazuoncology.com/
- Ownership
- Privately Held (backing)
Irazu Oncology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Irazu Oncology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Irazu Oncology in its N-PORT filings yet. We sweep new filings monthly.